Every 11 minutes, someone in the United States dies from an opioid overdose. That is roughly 130 people every single day — more than car accidents, gun violence, or HIV at its peak. Yet a treatment proven to cut opioid mortality by 50% or more remains dramatically underused. Fewer than 25% of people with opioid use disorder receive medication-assisted treatment, according to SAMHSA (2023). The gap between what works and what people actually get is staggering. The Substance Abuse and Mental Health Services Administration (SAMHSA) provides comprehensive information on medication-based treatment approaches.
Why?
Stigma. Misinformation. The persistent myth that taking medication for addiction is just "replacing one drug with another." If you have heard that before — or believed it — keep reading. The science tells a completely different story.
What Medication-Assisted Treatment Actually Is (And What It Is Not)
Medication-assisted treatment — commonly called MAT — combines FDA-approved medications with counseling and behavioral therapies to treat substance use disorders. The key word is combines. Medication alone is not MAT. Therapy alone is not MAT. The integration of both is what produces outcomes that neither approach achieves independently.
The three FDA-approved medications for opioid use disorder are buprenorphine (brand names include Suboxone and Subutex), methadone, and naltrexone (brand name Vivitrol). Each works differently in the brain, but all share one purpose: stabilizing brain chemistry so the person can actually engage in recovery without being hijacked by cravings and withdrawal.
Here is what MAT is not: it is not a shortcut. It is not "the easy way out." And it is absolutely not trading one addiction for another. The National Institute on Drug Abuse (NIDA, 2024) is unambiguous: "These medications do not create a new addiction. They restore balance to the brain circuits affected by addiction." When someone with diabetes takes insulin, nobody calls that "replacing one disease with another." MAT works on the same principle — treating a chronic medical condition with evidence-based medicine.
If you are exploring treatment options, understanding the full spectrum matters. RehabFlow offers a detailed breakdown of medication-assisted treatment programs and how they fit into broader recovery plans.
How MAT Works in the Brain: The Science Behind the Recovery
To understand why MAT works, you need to understand what opioids do to the brain — and why quitting cold turkey so often fails.
Opioids flood the brain with dopamine, the neurotransmitter responsible for pleasure and reward. Over time, the brain adapts. It produces less dopamine on its own. It reduces the number of dopamine receptors. The result? Without opioids, the person does not just feel bad — they feel a profound, chemical emptiness that no amount of willpower can override. This is not weakness. This is neuroscience.
Marcus is 34. He has been using oxycodone for three years, starting after a construction injury. He tries to quit on his own. By hour 18, his legs cramp so severely he cannot stand. His skin crawls. His mind tells him, with absolute certainty, that one pill will fix everything. He is not making a choice. His brain is making a demand. By hour 24, he uses again. This cycle repeats eleven times before he hears about MAT from a coworker who has been stable on Suboxone for two years.
MAT medications interrupt this cycle at the neurological level:
- Buprenorphine (Suboxone, Subutex) is a partial opioid agonist. It activates the same receptors as opioids but only partially — enough to prevent withdrawal and reduce cravings, not enough to produce a high. Think of it as fitting into the lock but only turning it halfway. According to a Cochrane Review (2014, updated 2020), buprenorphine maintenance treatment retains patients in treatment and suppresses illicit opioid use significantly better than placebo. The combination product Suboxone also includes naloxone, which discourages misuse by injection. For a detailed comparison, see RehabFlow's methadone vs. Suboxone guide.
- Methadone is a full opioid agonist. It activates opioid receptors fully but does so slowly and steadily, preventing the euphoric rush while eliminating withdrawal. Methadone has been used since the 1960s and has the longest evidence base of any addiction medication. It must be dispensed through certified opioid treatment programs (OTPs), which means daily clinic visits initially — a barrier for some, a structure for others. NIDA reports that methadone reduces opioid use, criminal activity, and HIV transmission.
- Naltrexone (Vivitrol) is an opioid antagonist — it blocks opioid receptors entirely. If someone on Vivitrol takes an opioid, they feel nothing. No high. No reward. The extended-release injectable form (given once monthly) eliminates the daily compliance challenge. However, the person must be fully detoxed before starting — typically 7 to 14 days opioid-free — which makes medical detox a critical first step. For more on how Vivitrol compares, visit our Vivitrol vs. Suboxone comparison.
The Numbers Do Not Lie: MAT Success Rates and Outcomes
Here is the aha moment most people miss: medication-assisted treatment does not just help people stop using — it keeps them alive.
A landmark study published in the journal BMJ (Sordo et al., 2017) found that patients in methadone or buprenorphine treatment had a 50% lower risk of all-cause mortality compared to those not in treatment. Not 10%. Not 20%. Half as likely to die.
Additional data from SAMHSA (2023) shows that MAT for opioid use disorder increases treatment retention by 75%, reduces illicit opioid use by 50-80%, decreases criminal activity associated with drug use, reduces the risk of infectious disease transmission (HIV, hepatitis C), and improves social functioning including employment and family relationships. These are not marginal improvements. These are transformative outcomes backed by decades of research across dozens of countries.
And yet, the "replacing one drug with another" myth persists. Consider this: the relapse rate for opioid use disorder treated with detox alone (no medication) is approximately 80-90% within the first year, according to NIDA. With MAT, retention rates at 12 months range from 50-80% depending on the medication and program. The evidence is not subtle.
Who Is MAT For? (The Answer May Surprise You)
MAT is most commonly associated with opioid use disorder — heroin, fentanyl, prescription painkillers like oxycodone and hydrocodone. But that is not the complete picture.
Naltrexone (both oral and injectable Vivitrol) is also FDA-approved for alcohol use disorder. It reduces the pleasurable effects of drinking, making it easier to abstain or reduce consumption. Acamprosate (Campral) and disulfiram (Antabuse) are additional FDA-approved medications for alcohol addiction.
MAT may be appropriate for you or a loved one if there is a diagnosed opioid or alcohol use disorder, if previous attempts at abstinence-only treatment have not worked, if there are co-occurring mental health conditions (MAT can stabilize the person enough to engage in dual diagnosis treatment), or if the risk of relapse is high due to environment, history, or severity of dependence.
Elena is 28. She completed a 30-day inpatient program twice. Both times, she relapsed within two weeks of discharge. Not because she did not try — she tried desperately. Her counselor at the second facility finally suggested buprenorphine. "I felt like a failure for needing it," she says. Six months later, she has not used. She goes to therapy weekly. She has a job. She calls her mother on Sundays again. The medication did not do the work for her — it gave her a foundation stable enough to do the work herself.
To understand how different treatment levels work together, explore inpatient vs. outpatient options or consider whether a 30-day or 90-day program fits your situation best.
What to Expect: The MAT Process From Start to Finish
Starting MAT is not as complicated as many people fear. Here is what the process typically looks like:
Step 1: Assessment. A physician or addiction specialist evaluates the type and severity of substance use, medical history, mental health status, and previous treatment attempts. This is not a judgment session — it is a diagnostic one. Be honest. The more accurate the picture, the better the treatment match.
Step 2: Medication selection. Based on the assessment, the provider recommends a specific medication. Factors include the substance used, the person's lifestyle (can they visit a clinic daily for methadone, or is monthly Vivitrol more practical?), medical history, and personal preference. You have a voice in this decision.
Step 3: Induction. For buprenorphine, the person must be in mild to moderate withdrawal before the first dose — typically 12-24 hours after last opioid use. This prevents a reaction called precipitated withdrawal. For methadone, dosing starts low and increases gradually. For Vivitrol, complete detox is required first.
Step 4: Stabilization. Over days to weeks, the dose is adjusted until cravings and withdrawal are controlled without sedation or euphoria. This phase requires patience and communication with the prescriber.
Step 5: Maintenance. Once stabilized, the person continues medication while actively engaging in counseling, therapy, support groups, and life rebuilding. This phase can last months, years, or indefinitely — and that is okay. There is no universal timeline for healing.
Ready to start the conversation? Call RehabFlow at (855) 321-3614 to discuss MAT options, insurance coverage, and program availability. The call is free, confidential, and could be the most important one you make.
Cost, Insurance, and Access: Breaking Down the Barriers
Cost should never be the reason someone dies of an overdose. And increasingly, it does not have to be.
The Mental Health Parity and Addiction Equity Act requires most insurance plans to cover substance use disorder treatment at the same level as other medical conditions. In practice, this means MAT is covered by most major insurers.
Blue Cross Blue Shield covers buprenorphine and methadone maintenance in most plans, typically requiring prior authorization. Aetna covers all three FDA-approved MAT medications with varying copay structures. UnitedHealthcare provides coverage for MAT as part of their behavioral health benefits. Cigna covers MAT with prior authorization and often requires concurrent counseling — which should be part of the plan anyway. Medicaid covers MAT in all 50 states, though specific medications and access points vary by state.
Without insurance, monthly costs range from approximately $200-600 for Suboxone (generic buprenorphine/naloxone is at the lower end), $300-500 for methadone clinic fees, and $1,000-1,500 for monthly Vivitrol injections (though manufacturer assistance programs exist).
Not sure what your insurance covers? RehabFlow's insurance verification page can help you check your benefits in minutes. Or call (855) 321-3614 — a specialist can verify your coverage over the phone.
Common Myths About MAT — And Why They Are Dangerous
"MAT is just replacing one drug with another." This is the most damaging myth in addiction medicine. Illicit opioid use involves uncontrolled doses of unpredictable substances, often contaminated with fentanyl, used in ways that create euphoria and crash cycles. MAT medications are administered in controlled, consistent doses under medical supervision. They stabilize — they do not intoxicate. The pharmacology is fundamentally different. Repeating this myth costs lives.
"You are not really sober if you take MAT." Sobriety is not defined by the absence of all medication. It is defined by the presence of a functioning, self-directed life free from the compulsive use of substances. A person on buprenorphine who goes to work, raises their children, and contributes to their community is in recovery. Full stop.
"MAT should only be short-term." Some people do well tapering off medication after 6-12 months. Others need it for years. Some need it indefinitely. The American Society of Addiction Medicine (ASAM) recommends against arbitrary time limits on MAT. The question is not "how long" but "what produces the best outcome for this individual."
"I can just detox and use willpower." You can also set a broken leg without a cast if you want. The question is why you would choose a less effective approach when a more effective one exists. Detox alone, without ongoing treatment, has relapse rates of 80-90% for opioid use disorder. That is not a willpower problem — it is a treatment adequacy problem.
Frequently Asked Questions About Medication-Assisted Treatment
How long does MAT last?
There is no one-size-fits-all answer. SAMHSA recommends a minimum of 12 months for opioid use disorder, but many people benefit from longer durations. Research consistently shows that longer treatment retention correlates with better outcomes. The decision to taper should be made collaboratively between you and your provider based on stability, support systems, and risk factors — never based on an arbitrary deadline or external pressure.
Can I get MAT through an outpatient program?
Yes. In fact, most MAT is delivered in outpatient settings. Buprenorphine can be prescribed by qualified providers in office-based settings. Methadone requires visits to certified OTPs. Vivitrol injections can be administered in any medical office. Many people begin with inpatient rehab for stabilization and transition to outpatient programs or intensive outpatient for ongoing MAT and therapy.
Will MAT show up on a drug test?
Standard workplace drug panels (5-panel tests) do not test for buprenorphine or methadone. However, extended panels (10-12 panel) may detect them. If you are prescribed these medications, you have legal protections under the Americans with Disabilities Act (ADA). Your prescribing physician can provide documentation. Vivitrol (naltrexone) does not show up on any standard drug test because it is not an opioid — it is an opioid blocker.
Is MAT covered by insurance?
Most private insurance plans and all state Medicaid programs cover MAT medications and associated counseling. The Mental Health Parity and Addiction Equity Act mandates this coverage. However, specific coverage details — copays, prior authorizations, preferred medications — vary by plan. Call your insurance provider directly, or let RehabFlow verify your benefits at (855) 321-3614. We check coverage specifics so you know exactly what to expect before treatment begins.
Can I take MAT if I am pregnant?
Yes — and it is strongly recommended over attempting detox during pregnancy. Opioid withdrawal during pregnancy carries risks including miscarriage, preterm labor, and fetal distress. Both methadone and buprenorphine are considered safe during pregnancy, with methadone having the longer track record. ACOG (American College of Obstetricians and Gynecologists) explicitly recommends MAT for pregnant women with opioid use disorder. Naltrexone is generally not recommended during pregnancy due to limited safety data.
What happens if I relapse while on MAT?
Relapse does not mean failure — it means the treatment plan needs adjustment. Your provider may modify your medication dose, increase counseling frequency, add peer support, or recommend a higher level of care. If you are on buprenorphine and use opioids on top of it, the buprenorphine will blunt the effects, reducing overdose risk. If you are on Vivitrol and use opioids, you will not feel them — but this also means you should not try to "override" the block by using large amounts, as this can be fatal once the naltrexone wears off.
Taking the First Step Toward Evidence-Based Recovery
Every hour you wait is another hour spent in the cycle that MAT was designed to break.
The evidence is overwhelming. The medications are available. The insurance coverage exists. The only remaining barrier is the decision to reach out — and you do not have to make that decision alone.
Call RehabFlow at (855) 321-3614 for a free, confidential conversation about your options. Whether you are considering MAT for yourself, a partner, a child, or a friend, our team can walk you through the process, verify your insurance, and connect you with providers who understand that addiction is a medical condition deserving medical treatment.
Recovery is not about being strong enough to do it alone. It is about being wise enough to use every tool available. MAT is one of the most powerful tools that exists.
Sources
- National Institute on Drug Abuse (NIDA). "Medications to Treat Opioid Use Disorder." Updated January 2024.
- Substance Abuse and Mental Health Services Administration (SAMHSA). "Medication-Assisted Treatment (MAT)." 2023.
- Sordo, L., et al. "Mortality risk during and after opioid substitution treatment." BMJ, 2017; 357: j1550.
- Cochrane Database of Systematic Reviews. "Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence." Updated 2020.
- American Society of Addiction Medicine (ASAM). "The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder." 2020.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting or changing any treatment. Individual results may vary. If you are experiencing a medical emergency, call 911 immediately.
Updated March 2026
